Effect of febuxostat on adverse events and mortality in gout in Taiwan: An interrupted time series analysis.
Ping-Han TsaiChang Fu KuoJia-Rou LiuPei-Ru LiLai-Chu SeePublished in: International journal of rheumatic diseases (2023)
Febuxostat may reduce SJS and TEN in all gout patients but increase AMI, PCI, and all-cause mortality in gout patients with comorbidities.
Keyphrases
- uric acid
- end stage renal disease
- acute myocardial infarction
- newly diagnosed
- ejection fraction
- chronic kidney disease
- coronary artery disease
- prognostic factors
- percutaneous coronary intervention
- cardiovascular disease
- type diabetes
- st segment elevation myocardial infarction
- antiplatelet therapy
- patient reported outcomes
- left ventricular